Claims for Patent: 9,738,718

Summary for Patent: 9,738,718

Title:	ICOS binding proteins
Abstract:	The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
Inventor(s):	Liu; Yao-Bin (Collegeville, PA), Mayes; Patrick (Collegeville, PA), Parmar; Radha Shah (Stevenage, GB)
Assignee:	GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)
Application Number:	15/387,161
Patent Claims:	1. A method of treating a cancer in a human in need thereof, which method comprises administering an ICOS binding protein or antigen binding portion thereof to said human, wherein the ICOS binding protein or antigen binding portion thereof cross-competes for binding to human ICOS with a reference antibody or antigen binding portion thereof comprising a V.sub.H domain comprising an amino acid sequence set forth in SEQ ID NO:7; and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:8, and administering an anti-PD-1 antibody to said human. 2. The method of claim 1 wherein the ICOS binding protein or antigen binding portion thereof binds to human ICOS with (i) an association rate constant (k.sub.on) of at least 1.times.10.sup.5 M.sup.-1s.sup.-1; and a dissociation rate constant (k.sub.off) of less than 6.times.10.sup.-5 s.sup.-1; or (ii) a dissociation constant (K.sub.D) of less than about 100 nM, wherein the affinity is measured by BIAcore. 3. The method of claim 1 wherein the anti-PD-1 antibody is nivolumab. 4. The method of claim 1 wherein the anti-PD-1 antibody is pembrolizumab. 5. The method of claim 1 wherein the ICOS binding protein is a monoclonal antibody. 6. The method of claim 5 wherein the monoclonal antibody is humanized or fully human. 7. The method of claim 1 wherein said cancer is colorectal cancer (CRC). 8. The method of claim 1 wherein said cancer is esophageal cancer. 9. The method of claim 1 wherein said cancer is cervical cancer. 10. The method of claim 1 wherein said cancer is bladder cancer. 11. The method of claim 1 wherein said cancer is breast cancer. 12. The method of claim 1 wherein said cancer is head and neck cancer. 13. The method of claim 1 wherein said cancer is ovarian cancer. 14. The method of claim 1 wherein said cancer is melanoma. 15. The method of claim 1 wherein said cancer is renal cell carcinoma (RCC). 16. The method of claim 1 wherein said cancer is EC squamous cell. 17. The method of claim 1 wherein said cancer is non-small cell lung carcinoma. 18. The method of claim 1 wherein said cancer is mesothelioma. 19. The method of claim 1 wherein said cancer is prostate cancer. 20. The method of claim 1 wherein said cancer is gastric cancer.

Details for Patent 9,738,718

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2039-02-26
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2039-02-26
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2039-02-26
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2039-02-26
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2039-02-26